Enhanced liver fibrosis score as a surrogate of liver-related complications and mortality in primary biliary cholangitis.
Journal
Medicine
ISSN: 1536-5964
Titre abrégé: Medicine (Baltimore)
Pays: United States
ID NLM: 2985248R
Informations de publication
Date de publication:
01 Oct 2021
01 Oct 2021
Historique:
received:
27
05
2021
accepted:
16
09
2021
entrez:
1
10
2021
pubmed:
2
10
2021
medline:
7
10
2021
Statut:
ppublish
Résumé
The presence of bridging fibrosis predicts survival of primary biliary cholangitis (PBC). This study aimed to compare serum parameters for the estimation of liver fibrosis and prediction of clinical outcomes in PBC.Out of 392 patients with PBC, 102 who underwent liver biopsy and in whom fibrosis indices, platelet count, hyaluronic acid, type IV collagen 7 second domain, procollagen type III amino-terminal peptide, tissue inhibitor of metalloproteinases 1, Mac-2 binding protein glycosylation isomer, N-terminal type III collagen propeptide levels; fibrosis index based on 4 factors, aspartate aminotransferase-to-platelet ratio index, and enhanced liver fibrosis (ELF) score were determined, were included. The correlation of histological stages based on both Scheuer and Nakanuma classifications with fibrosis indices was investigated. The Nakanuma system comprises grading for liver fibrosis and bile duct loss. Diagnostic performances of 10 fibrosis indices were evaluated to identify patients with poor prognosis. Moreover, correlations of those with PBC clinical manifestation and survival were also investigated.Enhances liver fibrosis (ELF) score had the highest correlation coefficient for liver fibrosis evaluated according to either the Scheuer or Nakanuma classification among 10 serum fibrosis indices. It also had the highest diagnostic performance in estimating Scheuer stage III and Nakanuma fibrosis score 2, both of which represent portal-bridging fibrosis. Patients with an ELF score of ≥10.0 had shorter survival and presented more frequently clinical complications than those with an ELF score of <10.0.ELF score determines the severity of liver fibrosis and predicts the occurrence of complications and survival in patients with PBC.
Identifiants
pubmed: 34596167
doi: 10.1097/MD.0000000000027403
pii: 00005792-202110010-00061
pmc: PMC8483841
doi:
Substances chimiques
Biomarkers
0
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
e27403Informations de copyright
Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc.
Déclaration de conflit d'intérêts
The authors have no conflicts of interests to disclose.
Références
Kawata K, Joshita S, Shimoda S, et al. The ursodeoxycholic acid response score predicts pathological features in primary biliary cholangitis. Hepatol Res 2020;51:80–9.
Hayashi M, Abe K, Fujita M, Okai K, Takahashi A, Ohira H. Changes in serum levels of leucine-rich alpha2-glycoprotein predict prognosis in primary biliary cholangitis. Hepatol Res 2019;49:385–93.
Namisaki T, Fujinaga Y, Moriya K, Yoshiji H. The association of histological progression with biochemical response to ursodeoxycholic acid in primary biliary cholangitis. Hepatol Res 2020;51:31–8.
Dulai PS, Singh S, Patel J, et al. Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis. Hepatology 2017;65:1557–65.
Hayashi M, Abe K, Fujita M, Takahashi A, Hashimoto Y, Ohira A. Serum Gas6 and Axl as non-invasive biomarkers of advanced histological stage in primary biliary cholangitis. Hepatol Res 2020;50:1337–46.
Takamura M, Matsuda Y, Kimura N, et al. Changes in disease characteristics of primary biliary cholangitis: an observational retrospective study from 1982 to 2016. Hepatol Res 2020;51:166–75.
McHutchison J, Poynard T, Afdhal N. International fibrosis group meeting participants. Fibrosis as an end point for clinical trials in liver disease: a report of the international fibrosis group. Clin Gastroenterol Hepatol 2006;4:1214–20.
Corpechot C, Carrat F, Poujol-Robert A, et al. Noninvasive elastography-based assessment of liver fibrosis progression and prognosis in primary biliary cirrhosis. Hepatology 2012;56:198–208.
Plebani M, Giacomini A, Floreani A, et al. Biochemical markers of hepatic fibrosis in primary biliary cirrhosis. Ric Clin Lab 1990;20:269–74.
Voumvouraki A, Koulentaki M, Notas G, Sfakianaki O, Kouroumalis E. Serum surrogate markers of liver fibrosis in primary biliary cirrhosis. Eur J Intern Med 2011;22:77–83.
Farkkila M, Rautiainen H, Karkkainen P, Karvonen AL, Nurmi H, Niemela O. Serological markers for monitoring disease progression in noncirrhotic primary biliary cirrhosis on ursodeoxycholic acid therapy. Liver Int 2008;28:787–97.
Zhang HC, Hu RF, Zhu T, Tong L, Zhang QQ. Primary biliary cirrhosis degree assessment by acoustic radiation force impulse imaging and hepatic fibrosis indicators. World J Gastroenterol 2016;22:5276–84.
Umemura T, Joshita S, Sekiguchi T, et al. Serum wisteria floribunda agglutinin-positive Mac-2-binding protein level predicts liver fibrosis and prognosis in primary biliary cirrhosis. Am J Gastroenterol 2015;110:857–64.
Joshita S, Umemura T, Usami Y, et al. Serum autotaxin is a useful disease progression marker in patients with primary biliary cholangitis. Sci Rep 2018;8:8159doi: 10.1038/s41598-018-26531-0.
doi: 10.1038/s41598-018-26531-0
Nishikawa H, Enomoto H, Iwata Y, et al. Impact of serum Wisteria floribunda agglutinin positive Mac-2-binding protein and serum interferon-gamma-inducible protein-10 in primary biliary cirrhosis. Hepatol Res 2016;46:575–83.
Osman KT, Maselli DB, Idilman IS, et al. Liver stiffness measured by either magnetic resonance or transient elastography is associated with liver fibrosis and is an independent predictor of outcomes among patients with primary biliary cholangitis. J Clin Gastroenterol 2020;55:449–57.
Friedrich-Rust M, Rosenberg W, Parkes J, Herrmann E, Zeuzem S, Sarrazin C. Comparison of ELF, FibroTest and FibroScan for the non-invasive assessment of liver fibrosis. BMC Gastroenterol 2010;10:103doi: 10.1186/1471-230X-10-103.
doi: 10.1186/1471-230X-10-103
Mayo MJ, Parkes J, Adams-Huet B, et al. Prediction of clinical outcomes in primary biliary cirrhosis by serum enhanced liver fibrosis assay. Hepatology 2008;48:1549–57.
Kakuda Y, Harada K, Sawada-Kitamura S, et al. Evaluation of a new histologic staging and grading system for primary biliary cirrhosis in comparison with classical systems. Hum Pathol 2013;44:1107–17.
Working Subgroup for Clinical Practice Guidelines for Primary Biliary C.Guidelines for the management of primary biliary cirrhosis: The Intractable Hepatobiliary Disease Study Group supported by the Ministry of Health, Labour and Welfare of Japan. Hepatol Res 2014;44 Suppl S1:71–90.
Scheuer P. Primary biliary cirrhosis. Proc R Soc Med 1967;60:1257–60.
Chazouilleres O, Wendum D, Serfaty L, Montembault S, Rosmorduc O, Poupon R. Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: clinical features and response to therapy. Hepatology 1998;28:296–301.
Casals G, Fernandez-Varo G, Melgar-Lesmes P, et al. Factors involved in extracellular matrix turnover in human derived cardiomyocytes. Cell Physiol Biochem 2013;32:1125–36.
Hogemann B, Voss B, Pott G, Rauterberg J, Gerlach U. 7 S collagen: a method for the measurement of serum concentrations in man. Clin Chim Acta 1984;144:01–10.
Jekarl DW, Choi H, Lee S, et al. Diagnosis of liver fibrosis with wisteria floribunda agglutinin-positive Mac-2 binding protein (WFA-M2BP) among chronic hepatitis B patients. Ann Lab Med 2018;38:348–54.
Nielsen MJ, Nedergaard AF, Sun S, et al. The neo-epitope specific PRO-C3 ELISA measures true formation of type III collagen associated with liver and muscle parameters. Am J Transl Res 2013;5:303–15.
Nakanuma Y, Zen Y, Harada K, et al. Application of a new histological staging and grading system for primary biliary cirrhosis to liver biopsy specimens: interobserver agreement. Pathol Int 2010;60:167–74.
Cholongitas E, Senzolo M, Standish R, et al. A systematic review of the quality of liver biopsy specimens. Am J Clin Pathol 2006;125:710–21.
DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988;44:837–45.
Carbone M, Sharp SJ, Flack S, et al. The UK-PBC risk scores: derivation and validation of a scoring system for long-term prediction of end-stage liver disease in primary biliary cholangitis. Hepatology 2016;63:930–50.
Namisaki T, Moriya K, Noguchi R, et al. Liver fibrosis progression predicts survival in patients with primary biliary cirrhosis. Hepatol Res 2017;47:E178–86.
Fujinaga Y, Namisaki T, Moriya K, et al. Identification of clinical risk factors for histological progression of primary biliary cholangitis. Hepatol Res 2019;49:1015–25.
Sekiguchi T, Umemura T, Fujimori N, et al. Serum cell death biomarkers for prediction of liver fibrosis and poor prognosis in primary biliary cirrhosis. PLoS One 2015;10:e0131658doi: 10.1371/journal.pone.0131658.
doi: 10.1371/journal.pone.0131658
Glen J, Floros L, Day C, Pryke R. Guideline Development Group. Non-alcoholic fatty liver disease (NAFLD): summary of NICE guidance. BMJ 2016;354:i4428doi: 10.1136/bmj.i4428.
doi: 10.1136/bmj.i4428
Are VS, Vuppalanchi R, Vilar-Gomez E, Chalasani N. Enhanced liver fibrosis score can be used to predict liver-related events in patients with nonalcoholic steatohepatitis and compensated cirrhosis. Clin Gastroenterol Hepatol 2021;19:1292–3.e3.
Trembling PM, Lampertico P, Parkes J, et al. Performance of Enhanced Liver Fibrosis test and comparison with transient elastography in the identification of liver fibrosis in patients with chronic hepatitis B infection. J Viral Hepat 2014;21:430–8.
Parkes J, Guha IN, Roderick P, et al. Enhanced Liver Fibrosis (ELF) test accurately identifies liver fibrosis in patients with chronic hepatitis C. J Viral Hepat 2011;18:23–31.
Inadomi C, Takahashi H, Ogawa Y, et al. Accuracy of the Enhanced Liver Fibrosis test, and combination of the Enhanced Liver Fibrosis and non-invasive tests for the diagnosis of advanced liver fibrosis in patients with non-alcoholic fatty liver disease. Hepatol Res 2020;50:682–92.
Anstee QM, Lawitz EJ, Alkhouri N, et al. Noninvasive tests accurately identify advanced fibrosis due to NASH: baseline data from the STELLAR trials. Hepatology 2019;70:1521–30.
Mehta SH, Lau B, Afdhal NH, Thomas DL. Exceeding the limits of liver histology markers. J Hepatol 2009;50:36–41.